Global significance and impact of dengue virus on human health

Mukesh Sharma[1], Surender Pal[2], Himanshu[3], Manish Kumar[4], Dr. Aasha Gandhi[5], Aarushi[6]
Assistant professor Sri Sukhmani Institute of Pharmacy[1], Student, Sri Sukhmani Institute of Pharmacy[2], Student, Sri Sukhmani Institute of Pharmacy[3], Assistant professor Sri Sukhmani Institute of Pharmacy[4], Principal, Sri Sukhmani Institute of Pharmacy[5], Assistant professor Shiva college of Pharmacy[6]

INTRODUCTION TO DENGUE

Dengue is a viral infection transmitted by Aedes mosquitoes, primarily Aedes aegypti. It is caused by four distinct but closely related dengue virus serotypes (DENV-1, DENV-2, DENV-3, and DENV-4). The disease is prevalent in tropical and subtropical regions, putting nearly half of the world's population at risk.

Dengue infections can range from asymptomatic to severe, potentially life-threatening conditions. The disease is characterized by flu-like symptoms, including high fever, severe headache, muscle and joint pain, and skin rash. In severe cases, it can progress to dengue haemorrhagic fever or dengue shock syndrome, which can be fatal if not properly managed [1].

Initial Infection

Mosquito bite introduces dengue virus into the bloodstream.

Incubation Period

Virus replicates in target cells for 3-14 days.

Symptom Onset

Fever, headache, and muscle pain.

Disease Progression

Symptoms worsen or resolve depending on severity.





Diagram of dengue virus:





The dengue virus is a roughly spherical structure composed of several key components:

- Envelope: The outer lipid bilayer derived from the host cell membrane, embedded with viral proteins.
- Capsid (C) Protein: A protein shell that encases and protects the viral RNA genome.
- Envelope (E) Protein: A glycoprotein crucial for virus attachment and entry into host cells.
- Membrane (M) Protein: Involved in virus assembly and maturation.
- RNA Genome: A single-stranded positive-sense RNA that carries the genetic information of the virus[2].

Pathogenesis and Immune Response

The pathogenesis of dengue involves a complex interplay between the virus and the host immune system. Upon infection, the virus triggers an innate immune response, activating interferons and other antiviral mechanisms. As the adaptive immune response develops, both humoral and cell-mediated immunity play crucial roles in viral clearance and protection against future infections.

However, the immune response can also contribute to disease severity, particularly in secondary infections with a different dengue serotype. This phenomenon, known as antibody-dependent enhancement (ADE), occurs when non-neutralizing antibodies from a previous infection bind to the new serotype, facilitating viral entry into host cells. ADE can lead to increased viral replication and a heightened inflammatory response, potentially resulting in severe dengue[3].

Epidemiology and Global Burden

Dengue has emerged as a major global health concern, with a dramatic increase in incidence over the past decades. The World Health Organization estimates that 390 million dengue infections occur annually, with about 96 million resulting in clinically apparent disease. The disease is endemic in over 100 countries across the Americas, Southeast Asia, Western Pacific, Africa, and Eastern Mediterranean regions[4].

Factors contributing to the spread of dengue include rapid urbanization, global travel, and climate change. These elements have expanded the geographical range of the Aedes mosquito vectors and increased human exposure to the virus. The economic burden of dengue is substantial, encompassing direct medical costs, vector control expenses, and lost productivity[5].

Transmission and Life Cycle of the Dengue Virus:

The dengue virus is primarily transmitted to humans through the bite of an infected female Aedes mosquito, most commonly Aedes aegypti. These mosquitoes thrive in urban environments and breed

in standing water containers. The virus enters the mosquito when it feeds on an infected person during the viraemic phase of illness. After an extrinsic incubation period of 8-12 days, the infected mosquito can transmit the virus to other humans during subsequent blood meals[6].

Once inside the human host, the dengue virus targets various cells, including dendritic cells, monocytes, and macrophages. The virus enters these cells through receptor-mediated endocytosis and undergoes replication within the cytoplasm. New viral particles are then assembled and released to infect more cells, perpetuating the cycle of infection[6].

Mosquito Bite

Infected Aedes mosquito injects virus into human bloodstream

Cellular Infection

Virus enters and replicates in target cells

Viremia

Virus spreads through bloodstream, infecting more cells

Transmission

Uninfected mosquito bites infected person, continuing the cycle

Effect of dengue on different organ in human body:

The dengue virus can affect multiple parts of the body, leading to various symptoms and potential complications. Here's how it impacts different systems:

1. Immune System

- Dengue targets white blood cells, reducing immunity and allowing the virus to spread more easily.
- It can cause a "cytokine storm," where excessive immune response leads to inflammation, damaging blood vessels and organs[7].

2. Circulatory System

- The virus causes blood vessel damage and capillary leakage, leading to hemorrhagic symptoms like bleeding gums, nosebleeds, and easy bruising.
- Severe cases lead to Dengue Hemorrhagic Fever (DHF) or Dengue Shock Syndrome (DSS), causing dangerously low blood pressure and shock.

3. Liver

- The liver often becomes inflamed (hepatitis), leading to elevated liver enzymes and, in severe cases, liver failure[8].

4. Gastrointestinal Tract

- Symptoms include nausea, vomiting, abdominal pain, and loss of appetite.
- Severe cases may lead to gastrointestinal bleeding, indicated by dark or bloody stools.

5. Skin

- A red rash and itchy skin are common, often appearing after the fever declines.
- Petechiae (small red spots) can also develop due to bleeding under the skin.

6. Muscles and Joints

- Known as "breakbone fever," dengue causes intense muscle and joint pain, often incapacitating the patient[9].

7. Central Nervous System (CNS)

- In rare cases, dengue can lead to neurological symptoms like seizures, encephalitis (brain inflammation), and mental confusion, particularly in severe infections.

8. Kidneys

- In advanced cases, dengue can impair kidney function, sometimes leading to kidney failure.

9. Heart

- Although rare, dengue can cause myocarditis (inflammation of the heart muscle), affecting the heart's ability to pump blood effectively.

The severity of dengue varies, with many cases presenting mild symptoms, while others escalate to life-threatening complications requiring medical intervention[7].

Clinical Manifestations and Diagnosis:

Dengue infections can manifest a wide spectrum of clinical presentations, ranging from asymptomatic to severe, life-threatening disease. The typical course of dengue fever includes an abrupt onset of high fever, severe headache, retro-orbital pain, myalgia, arthralgia, and rash. In some cases, the disease can progress to severe dengue, characterized by plasma leakage, severe bleeding, or organ impairment[10,11,12].

Diagnosis of dengue relies on a combination of clinical symptoms, physical examination, and laboratory tests. During the early stages of infection, virus isolation or nucleic acid detection methods such as RT-PCR can confirm the diagnosis. Later in the course of illness, serological tests to detect dengue-specific antibodies (IgM and IgG) are used. Rapid diagnostic tests are available for point-of-care testing, although their sensitivity and specificity vary.

Common Symptoms:

High fever, severe headache, muscle and joint pain, nausea, vomiting, skin rash, and fatigue

Warning Signs

Abdominal pain, persistent vomiting, mucosal bleeding, lethargy, liver enlargement, and increasing haematocrit with decreasing platelets

Severe Dengue

Severe plasma leakage, severe bleeding, or severe organ impairment

Diagnostic Methods

Virus isolation, RT-PCR, NS1 antigen detection, and serological tests for IgM and IgG antibodies

Current Treatment Strategies:

Currently, there is no specific antiviral treatment for dengue. Management primarily focuses on supportive care and careful monitoring of patients. The cornerstone of treatment is maintaining adequate fluid balance, as severe dengue can lead to significant plasma leakage and hypovolemic shock. Oral rehydration is sufficient for most cases, but intravenous fluid therapy may be necessary for severe cases.

Pain management typically involves acetaminophen, while non-steroidal anti-inflammatory drugs (NSAIDs) are avoided due to the risk of bleeding complications. Close monitoring of vital signs, haematocrit, and platelet counts is essential to detect early signs of disease progression. In cases of severe bleeding, blood transfusions may be required. Intensive care support, including mechanical ventilation and vasopressor therapy, may be necessary for patients with severe dengue and organ dysfunction[13,14].

Fluid Management

Oral rehydration for mild cases, intravenous fluids for severe cases

Symptom Relief

Acetaminophen for fever and pain, avoid NSAIDs

Monitoring

Regular assessment of vital signs, haematocrit, and platelet counts

Severe Cases

Blood transfusions, intensive care support as needed

Challenges in Dengue Management:

Dengue management faces numerous challenges, ranging from clinical complexities to public health obstacles. One significant challenge is the difficulty in predicting which patients will progress to severe dengue, necessitating close monitoring of all cases. The lack of specific antiviral treatments limits therapeutic options, placing a heavy reliance on supportive care.

Vector control remains a major challenge in dengue prevention. The adaptability of Aedes mosquitoes to urban environments and their resistance to insecticides complicate eradication efforts. Additionally, the co-circulation of multiple dengue serotypes and the potential for antibody-dependent enhancement make vaccine development particularly challenging. Limited healthcare resources in many endemic areas further compound these issues, hindering effective diagnosis, treatment, and surveillance efforts[15].

Clinical Challenges
- Predicting severe cases - Lack of specific antivirals
- Managing complications

Vector Control Issues

- Mosquito adaptability - Insecticide resistance - Urban breeding sites

Public Health Hurdles

- Limited resources - Surveillance difficulties - Vaccine development complexities

Emerging Dengue Vaccines and Therapeutics:

The development of dengue vaccines has been a priority in recent years. The first licensed dengue vaccine, (CYD-TDV), is a live attenuated tetravalent vaccine. However, its use is limited to individuals with prior dengue exposure due to an increased risk of severe dengue in seronegative individuals. Several other vaccine candidates are in various stages of clinical trials, including live attenuated, subunit, and DNA vaccines, aiming to provide safe and effective protection against all four serotypes.

On the therapeutic front, researchers are exploring various approaches to develop specific antiviral treatments for dengue. These include viral enzyme inhibitors, host-targeted antivirals, and antibody-based therapies. Some promising candidates in clinical trials include nucleoside analogues targeting viral RNA polymerase and compounds that inhibit viral entry or replication. Additionally, monoclonal antibodies capable of neutralizing multiple dengue serotypes are being investigated as potential therapeutic and prophylactic agents[16,17,18].

Regional data on dengue virus:

Dengue virus is a significant public health concern in many regions worldwide, particularly in tropical and subtropical areas. Here's a breakdown of the regional distribution and impact:

Southeast Asia and Western Pacific:

- Highest burden: This region bears the brunt of the global dengue burden, with countries like India, Indonesia, Philippines, Thailand, and Vietnam being heavily affected.
- Endemic and epidemic cycles: Dengue is endemic in these countries, with periodic outbreaks reaching epidemic proportions.
- Diverse serotypes: All four serotypes of the virus circulate in this region, contributing to complex epidemiological patterns.

Americas:

- Expanding geographic range: Dengue has been rapidly expanding its range in the Americas, with countries like Brazil, Mexico, and Colombia experiencing significant outbreaks.
- Urbanization and climate change: These factors contribute to the increasing risk of dengue transmission in urban areas.
- Emergence of DENV-4: The emergence of DENV-4 in recent years has added to the complexity of the epidemiological situation.
- Africa:
- Sub-Saharan Africa: Dengue is endemic in many parts of sub-Saharan Africa, particularly in urban areas.
- Emerging threat: The disease is increasingly recognized as a significant public health problem in this region.
- Limited surveillance: Challenges in surveillance and control efforts hinder a comprehensive understanding of the dengue burden.

Europe:

- Imported cases: While dengue is not endemic in Europe, imported cases from affected regions are increasingly reported.
- Potential for outbreaks: Climate change and increased travel could create conditions favourable for local transmission in certain areas[19,20].

It's important to note that the regional distribution and impact of dengue can vary over time due to factors such as climate change, urbanization, and changes in virus circulation patterns. Effective surveillance, vector control measures, and public health interventions are crucial to mitigate the burden of dengue in affected regions[21,22,23,24,25,26,27].

DENGUE SITUATION IN INDIA:

Dengue Cases and Deaths in the Country since 2019

*Provisional till 30th June 2024

C=Cases | D=Deaths | NR=Not Reported

2023: WB reported data till 13.9.2023

2024: WB reported data till 21.2.2024

FUTURE RESEARCH DIRECTIONS AND PROSPECTS

Future research in dengue will likely focus on several key areas to improve prevention, diagnosis, and treatment. In vaccine development, efforts will continue to create a safe and effective vaccine that provides balanced protection against all four serotypes without the risk of antibody-dependent enhancement. Novel vaccine platforms, such as mRNA vaccines, may offer new possibilities in this field[28,29,30,31].

Advances in genomics and proteomics are expected to enhance our understanding of dengue pathogenesis and host-virus interactions, potentially leading to new therapeutic targets. The development of rapid, accurate, and affordable point-of-care diagnostic tests remains a priority to improve early detection and management of dengue cases. In vector control, innovative approaches such as the use of Wolbachia-infected mosquitoes or gene drive technologies may offer new tools for reducing dengue transmission[32,33].

Integrating artificial intelligence and big data analytics into dengue surveillance and outbreak prediction could revolutionize public health responses. As climate change continues to influence vector distribution, research into the environmental determinants of dengue transmission will be crucial for developing adaptive strategies. Ultimately, a multidisciplinary approach combining biomedical research, public health interventions, and technological innovations will be essential in the global effort to control and potentially eliminate dengue as a public health threat [34,35,36].

Improved Vaccines

Development of safe and effective vaccines against all serotypes[37,38].

Advanced Diagnostics

Rapid and accurate point-of-care tests for early detection [39].

Innovative Vector Control

Novel approaches to reduce mosquito populations and transmission [40,41].

CONCLUSION

Dengue virus poses a significant global health concern, particularly in tropical and subtropical regions. While most infections are asymptomatic or mild, a subset of cases can progress to severe dengue, which can be life-threatening. The virus is primarily transmitted by Aedes mosquitoes, emphasizing the importance of vector control measures for prevention. Currently, there is no specific antiviral treatment for dengue, making prevention and early diagnosis crucial. Ongoing research aims to develop effective vaccines and therapeutic interventions to combat this widespread disease.

REFERENCES

[1] Halstead SB. Pathogenesis of dengue: Challenges to molecular biology. Science. 1988;239:476–81. doi: 10.1126/science.3277268. [DOI] [PubMed] [Google Scholar]

[2] Kurane I. Dengue hemorrhagic fever with special emphasis on immunopathogenesis. Comp Immunol Microbiol Infect Dis. 2007;30:329–40. doi: 10.1016/j.cimid.2007.05.010. [DOI] [PubMed] [Google Scholar]

[3] Gubler DJ. Dengue and dengue Hemorrhagic fever. Clin Microbiol Rev. 1998;11:480–96. doi: 10.1128/cmr.11.3.480. [DOI] [PMC free article] [PubMed] [Google Scholar]

[4] New ed. Geneva, Switzerland: World Health Organization; 2009. World Health Organization (WHO). Dengue- Guidelines for Diagnosis, Treatment, Prevention and Control. [PubMed] [Google Scholar]

[5] Guzman MG, Halstead SB, Artsob H, Buchy P, Farrar J, Gubler DJ, et al. Dengue: A continuing global threat. Nat Rev Microbiol. 2010;8(Suppl):S7–16. doi: 10.1038/nrmicro2460. [DOI] [PMC free article] [PubMed] [Google Scholar]

[6] Linares EM, Pannuti CS, Kubota LT, Thalhammer S. Immunospot assay based on fluorescent nanoparticles for dengue fever detection. Biosens Bioelectron. 2013;41:180–5. doi: 10.1016/j.bios.2012.08.005. [DOI] [PubMed] [Google Scholar]

[7] San Martin JL, Brathwaite O, Zanbrano B, Solorzano JO, Bouckenooghe A, Dayan GH, et al. The epidemiology of dengue in the Americas over the last three decades: A worrisome reality. Am J Tropical Med Hyg. 2010;82:128–35. doi: 10.4269/ajtmh.2010.09-0346. [DOI] [PMC free article] [PubMed] [Google Scholar]

[8] Gupta N, Srivastava S, Jain A, Chaturvedi UC. Dengue in India. Indian J Med Res.

2012;136:373–90. [PMC free article] [PubMed] [Google Scholar]

[9] Thomas EA, John M, Bhatia A. Muco-Cutaneous manifstations of dengue viral infection in Punjab. Int J Dermatol. 2007;46:715–19. doi: 10.1111/j.1365-4632.2007.03298.x. [DOI] [PubMed] [Google Scholar]

[10] Arshad I, Malik FA, Hussain A, Shah SA. Dengue fever: Clinico-pathologic correlations and their association with poor outcome. Professional Med J. 2011;18:57–63. [Google Scholar]

[11] Wu SJ, Grouard-Vigel G, Sun W, Mascola JR, Brachel E, Putvatana R, et al. Human skin langerhans cells are targets of dengue virus infection. Nat Med. 2000;6:816–20. doi: 10.1038/77553. [DOI] [PubMed] [Google Scholar]

[12] Bhamarapravati N. Pathology and Pathogenesis of DHF. New Delhi: WHO Meeting; 1980. [Google Scholar]

[13] Whitehorn J, Simmons CP. The pathogenesis of dengue. Vaccine. 2011;29:7221–8. doi: 10.1016/j.vaccine.2011.07.022. [DOI] [PubMed] [Google Scholar]

[14] Guzman MG, Kouri G. Dengue and dengue hemorrhagic fever in the Americas: Lessons and challenges. J Clin Virol. 2003;27:1–13. doi: 10.1016/s1386-6532(03)00010-6. [DOI] [PubMed] [Google Scholar]

[15] Revised and Expanded ed. New Delhi: WHO; 2011. World Health Organization. Comprehensive Guidelines for Prevention and Control of Dengue and Dengue Haemorrhagic Fever. [Google Scholar]

[16] Whitehorn J, Farrar J. Dengue. Br Med Bull. 2010;95:161–73. doi: 10.1093/bmb/ldq019. [DOI] [PubMed] [Google Scholar]

[17] Geneva, Switzerland: World Health Organization; 2009. WHO. Dengue: Guidelines for Diagnosis, Treatment, Prevention and Control. Part 1.1.6: Dengue case classification; pp. 10–2. [PubMed] [Google Scholar]

[18] Ranjit S, Kissoon N. Dengue hemorrhagic fever and shock syndromes. Pediatr Crit Care Med. 2011;12:90–100. doi: 10.1097/PCC.0b013e3181e911a7. [DOI] [PubMed] [Google Scholar]

[19] 2nd ed. Geneva (Switzerland): World Health Organization; 1997. WHO. Clinical diagnosis. Chapter 2. Dengue Haemorrhagic Fever: Diagnosis, Treatment, Prevention and Control; pp. 12–23. [Google Scholar]

[20] Ahmed FU, Mahmood CB, Sharma JD, Hoque SM, Zaman R, Hasan MH. Dengue fever and dengue haemorrhagic fever in chidren the 2000 out break in Chittatong, Bangladesh. Dengue Bulletin. 2001;25:33–9. [Google Scholar]

[21] Narayanan M, Aravind MA, Thilothammal N, Prema R, Sargunam CS, Ramamurty N. Dengue fever epidemic in Chennai-a study of clinical profile and outcome. Indian Pediatr. 2002;39:1027–33. [PubMed] [Google Scholar]

[22] Chen LH, Wilson ME. Dengue and chikungunya infections in travelers. Curr Opin Infect Dis. 2010;23:438–44. doi: 10.1097/QCO.0b013e32833c1d16. [DOI] [PubMed] [Google Scholar]

[23] Waterman SH, Gubler DJ. Dengue fever. Clin Dermatol. 1989;7:117–22. doi: 10.1016/0738-081x(89)90034-5. [DOI] [PubMed] [Google Scholar]

[24] Itoda I, Masuda G, Suganuma A, Imamura A, Ajisawa A, Yamada K, et al. Clinical features of 62 imported cases of dengue fever in Japan. Am J Trop Med Hyg. 2006;75:470–4. [PubMed] [Google Scholar]

[25] Radakovic-Fijan S, Graninger W, Müller C, Hönigsmann H, Tanew A. Dengue hemorrhagic fever in a British travel guide. J Am Acad Dermatol. 2002;46:430–3. doi: 10.1067/mjd.2002.111904. [DOI] [PubMed] [Google Scholar]

[26] Chadwick D, Arch B, Wilder-Smith A, Paton N. Distinguishing dengue fever from other infections on the basis of simple clinical and laboratory features: Application of logistic regression analysis. J Clin Virol. 2006;35:147–53. doi: 10.1016/j.jcv.2005.06.002. [DOI] [PubMed] [Google Scholar]

[27] Kabra SK, Juneja R, Madhulika, Jain Y, Singhal T, Dar L, et al. Myocardial dysfunction in children with dengue haemorrhagic fever. Natl Med J India. 1998;11:59–61. [PubMed] [Google Scholar]

[28] Halstead SB, Lan NT, Myint TT, Shwe TN, Nisalak A, Kalyanarooj S, et al. Dengue

hemorrhagic fever in infants: Research opportunities ignored. Emerg Infect Dis. 2002;8:1474–9. doi: 10.3201/eid0812.020170. [DOI] [PMC free article] [PubMed] [Google Scholar]

[29] National Institute of Communicable Diseases. Investigation and Control of Outbreaks: Dengue and Dengue Hemorrhagic Fever. 1997 [Google Scholar]

[30] Chiu YC, Wu KL, Kuo CH, Hu TH, Chou YP, Chuah SK, et al. Endoscopic findings and management of dengue patients with upper gastrointestinal bleeding. Am J Trop Med Hyg. 2005;73:441–4. [PubMed] [Google Scholar]

[31] La Russa VF, Innis BL. Mechanisms of dengue virus-induced bone marrow suppression. Baillieres Clin Haematol. 1995;8:249–70. doi: 10.1016/s0950-3536(05)80240-9. [DOI] [PubMed] [Google Scholar]

[32] Rosenfeld SJ, Young NS. Viruses and bone marrow failure. Blood Rev. 1991;5:71–7. doi: 10.1016/0268-960x(91)90037-d. [DOI] [PubMed] [Google Scholar]

[33] Phanichyakarn P, Pongpanich B, Israngkura PB, Dhanamitta S, Valyasevi A. Studies on dengue hemorrhagic fever. III. Serum complement (C3) and platelet studies. J Med Assoc Thai. 1977;60:301–6. [PubMed] [Google Scholar]

[34] Geneva: World Health Organization; 2001. World Health Organization. Dengue and dengue haemorrhagic fever. Chapter 6. WHO Report on Global Surveillance of Epidemic Prone Infectious Diseases. [Google Scholar]

[35] Richards AL, Bagus R, Baso SM, Follows GA, Tan R, Graham RR, et al. The first reported outbreak of dengue hemorrhagic fever in Irian Jaya, Indonesia. Am J Trop Med Hyg. 1997;57:49–55. doi: 10.4269/ajtmh.1997.57.49. [DOI] [PubMed] [Google Scholar]

[36] Srikiatkhachorn A, Krautrachue A, Ratanaprakarn W, Wongtapradit L, Nithipanya N, Kalayanarooj S, et al. Natural history of plasma leakage in dengue hemorrhagic fever: A serial ultrasonographic study. Pediatr Infect Dis J. 2007;26:283–90. doi: 10.1097/01.inf.0000258612.26743.10. [DOI] [PubMed] [Google Scholar]

[37] Gurugama P, Garg P, Perera J, Wijewickrama A, Seneviratne SL. Dengue viral infections. Indian J Dermatol. 2010;55:68–78. doi: 10.4103/0019-5154.60357. [DOI] [PMC free article] [PubMed] [Google Scholar]

[38] Shivpuri A, Shivpuri A. Dengue-An overview. Dent Med Probl. 2011;48:153–6. [Google Scholar]

[39] Sanford JP. Harrison's Principles of Internal Medicine. 12th ed. Vol. 1. New York: McGraw-Hill; 1986. [Google Scholar]

[40] Byatnal A, Mahajan N, Koppal S, Ravikiran A, Thriveni R, Parvathi Devi MK. Unusual yet isolated oral manifestations of persistent thrombocytopenia – A rare case report. Braz J Oral Sci. 2013;12:233–6. [Google Scholar]

[41] Mithra R, Baskaran P, Sathyakumar M. Oral presentation in dengue hemorrhagic fever: A rare entity. J Nat Sci Biol Med. 2013;4:264–7. doi: 10.4103/0976-9668.107324. [DOI] [PMC free article] [PubMed] [Google Scholar]